Apport des modèles expérimentaux: associations Synercid et beta-lactamines

Détails

ID Serval
serval:BIB_CD7DB475076F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Apport des modèles expérimentaux: associations Synercid et beta-lactamines
Périodique
Presse Médicale
Auteur⸱e⸱s
Moreillon P.
ISSN
0755-4982 (Print)
ISSN-L
0755-4982
Statut éditorial
Publié
Date de publication
2001
Volume
30
Numéro
25 Pt 2
Pages
X-XIV
Langue
français
Résumé
SYNERCID ALONE IN A RAT MODEL OF EXPERIMENTAL ENDOCARDITIS: Trials conducted using 2 injections daily showed that animals infected with meti-R resistant Staphylococcus aureus strains sensitive to erythromycin were cured in 3 days. The same is not true for infections caused by C-MLSB-R staphylococci. The daily dose cannot be increased due to the venous toxicity of Synercid, leading to the idea of testing Synercid in combination with other antibiotics. IN VITRO STUDIES: Several antibiotics have been tested in combination with Synercid. Several beta-lactams have been shown to exhibit an additive or synergetic effect on a collection of meti-R and meti-S S. aureus strains. IN VIVO STUDIES: In animals infected with C-MLSB-R meti-R S. aureus, the combination Synercid + cefepime increases the activity of cefipime and prevents selection of beta-lactam highly resistant strains. The results obtained with the Synercid + cefpirome combination are even more eloquent. Finally, Synercid, alone or in combination with these 2 cephalosporins, does not select resistant strains.
Mots-clé
Animals, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/adverse effects, Drug Synergism, Drug Therapy, Combination/adverse effects, Drug Therapy, Combination/therapeutic use, Endocarditis, Bacterial/drug therapy, Humans, Rats, Staphylococcal Infections/drug therapy, Virginiamycin/administration & dosage, Virginiamycin/adverse effects, beta-Lactams
Pubmed
Web of science
Création de la notice
24/01/2008 13:58
Dernière modification de la notice
20/08/2019 15:48
Données d'usage